Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 – Off-patent Chemo-regimens to Retain Dominance Despite New Launches – Acute Market Reports

Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 – Off-patent Chemo-regimens to Retain Dominance Despite New Launches

Browse Full Report Visit :- http://www.acutemarketreports.com/report/ovarian-cancer-therapeutics-in-asia-pacific-markets-to-2020-off-patent-chemo-regimens-to-retain-dominance-despite-new-launches


GBI Research, a leading business intelligence provider, has released its latest research report, “”Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 – Off-patent Chemo-regimens to Retain Dominance Despite New Launches””. The report provides estimates of the market size for 2013, along with forecasts until 2020 for the Asia-Pacific markets of India, China, Australia and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Ovarian Cancer (OC).

Platinum-based chemotherapy, predominantly the chemotherapy regimen paclitaxel and carboplatin, is the standard of care for the treatment of platinum-sensitive OC (both first-line and recurrent). The initial treatment is quite effective, with the majority of patients entering remission. However, almost all relapse, and after successive periods of remission and relapse either die or progress to platinum-resistant disease, for which the prognosis is poor. There is a clear gap in the market for maintenance therapies, as well as for more effective treatment options in platinum-resistant or refractory patients.


The report analyzes treatment usage patterns, drug types available and pipeline and market forecasts for OC. It covers and includes –

– A brief introduction to OC, including the disease’s pathogenesis, risk factors and diagnosis

– In-depth analysis of the drug combinations used in the treatment of OC, including analyses of their safety, efficacy, and place in the disease treatment algorithm, as well as a heat map comparing the drug combinations in terms of safety and efficacy


Reasons to buy

The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to –

– Understand the efficacy and safety of the current monotherapies and drug combinations used in the treatment of OC, with in-depth analysis of the disease treatment algorithm

– Understand the key signaling pathways and molecular targets currently under investigation in OC drug development

– Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent


Browse All Reports of This Category :- http://www.acutemarketreports.com/category/pharmaceutical-market

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7

2 Introduction 9
2.1 Disease Pathophysiology 9
2.1.1 Ovarian Cancer – A Group of Distinct Diseases 9
2.1.2 Ovarian Cancer is Highly Heterogenic with Multiple Mutations and Affected Signaling Pathways 10
2.2 Symptoms and Diagnosis 12
2.3 Risk Factors 14
2.3.1 Age 14
2.3.2 Inherited Genetic Mutations 14
2.3.3 Greater Number of Lifetime Ovulations 14
2.3.4 Weight 14
2.3.5 Previous Medical Conditions 14
2.4 Treatment Algorithm 14
2.4.1 Surgery 14
2.4.2 First-Line Chemotherapy 15
2.4.3 Maintenance Therapy 18
2.5 Recurrent Disease 20

3 Marketed Products 38
3.1 Carboplatin 38
3.2 Paclitaxel 39
3.3 Gemcitabine 40
3.4 Topotecan 41
3.5 Pegylated Liposomal Doxorubicin 41
3.6 Yondelis 42
3.7 Avastin 42

To Get Complete Report @ http://www.acutemarketreports.com/report/ovarian-cancer-therapeutics-in-asia-pacific-markets-to-2020-off-patent-chemo-regimens-to-retain-dominance-despite-new-launches

About Us:

Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements.We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the worlds most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.

Contact Us :

Name : Chris Paul


Designation : Global Sales Manager

Toll Free(US/CANADA): +1-855-455-8662

Email :  sales@acutemarketreports.com

Website : http://www.acutemarketreports.com

SOURCE Columnist of Week https://columnistofweek.com/